{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:21:14Z","timestamp":1789960874041,"version":"4.0.1"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL134366"],"award-info":[{"award-number":["R01HL134366"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R56HL143809"],"award-info":[{"award-number":["R56HL143809"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK120866"],"award-info":[{"award-number":["R01DK120866"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA221813"],"award-info":[{"award-number":["R01CA221813"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19AIREA34380223"],"award-info":[{"award-number":["19AIREA34380223"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009238","name":"Virginia Commonwealth University","doi-asserted-by":"publisher","award":["Pauley Pilot Research Grant"],"award-info":[{"award-number":["Pauley Pilot Research Grant"]}],"id":[{"id":"10.13039\/100009238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11010-022-04520-2","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T09:03:03Z","timestamp":1661763783000},"page":"679-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine\u2014a\u00a0possible prevention strategy for COVID-19?"],"prefix":"10.1007","volume":"478","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9484-3743","authenticated-orcid":false,"given":"Rakesh C.","family":"Kukreja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saisudha","family":"Koka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Samidurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-3329","authenticated-orcid":false,"given":"Lei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"4520_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/978-1-4614-5441-0_6","volume":"771","author":"E Ginter","year":"2012","unstructured":"Ginter E, Simko V (2012) Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol 771:42\u201350","journal-title":"Adv Exp Med Biol"},{"key":"4520_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jacc.2013.04.031","volume":"62","author":"GA Nichols","year":"2013","unstructured":"Nichols GA, Joshua-Gotlib S, Parasuraman S (2013) Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol 62:121\u2013127","journal-title":"J Am Coll Cardiol"},{"key":"4520_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/diacare.21.1.69","volume":"21","author":"H Miettinen","year":"1998","unstructured":"Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J (1998) Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21:69\u201375","journal-title":"Diabetes Care"},{"key":"4520_CR4","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.amjcard.2017.05.015","volume":"120","author":"F Paneni","year":"2017","unstructured":"Paneni F, Luscher TF (2017) Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Cardiol 120:S17\u2013S27. https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.015","journal-title":"Am J Cardiol"},{"key":"4520_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Investigators E (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"key":"4520_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.2174\/138161209787582066","volume":"15","author":"A Barsotti","year":"2009","unstructured":"Barsotti A, Giannoni A, Di NP, Emdin M (2009) Energy metabolism in the normal and in the diabetic heart. Curr Pharm Des 15:836\u2013840","journal-title":"Curr Pharm Des"},{"key":"4520_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1113\/JP271242","volume":"594","author":"LS Mansor","year":"2016","unstructured":"Mansor LS, Mehta K, Aksentijevic D, Carr CA, Lund T, Cole MA, Le Page L, Sousa Fialho Mda L, Shattock MJ, Aasum E, Clarke K, Tyler DJ, Heather LC (2016) Increased oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia signalling and metabolic adaptation. J Physiol 594:307\u2013320. https:\/\/doi.org\/10.1113\/JP271242","journal-title":"J Physiol"},{"key":"4520_CR8","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.2174\/1381612821666150710150445","volume":"21","author":"A Fukushima","year":"2015","unstructured":"Fukushima A, Milner K, Gupta A, Lopaschuk GD (2015) Myocardial energy substrate metabolism in heart failure: from pathways to therapeutic targets. Curr Pharm Des 21:3654\u20133664","journal-title":"Curr Pharm Des"},{"key":"4520_CR9","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","volume":"385","author":"RE Gilbert","year":"2015","unstructured":"Gilbert RE, Krum H (2015) Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385:2107\u20132117","journal-title":"Lancet"},{"key":"4520_CR10","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMra071667","volume":"357","author":"DM Yellon","year":"2007","unstructured":"Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121\u20131135","journal-title":"N Engl J Med"},{"key":"4520_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","volume":"18","author":"GS Baillie","year":"2019","unstructured":"Baillie GS, Tejeda GS, Kelly MP (2019) Therapeutic targeting of 3\u2019,5\u2019-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov 18:770\u2013796. https:\/\/doi.org\/10.1038\/s41573-019-0033-4","journal-title":"Nat Rev Drug Discov"},{"key":"4520_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13:290\u2013314. https:\/\/doi.org\/10.1038\/nrd4228","journal-title":"Nat Rev Drug Discov"},{"key":"4520_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1517\/14656566.2012.662220","volume":"13","author":"MK Frey","year":"2012","unstructured":"Frey MK, Lang I (2012) Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 13:747\u2013755. https:\/\/doi.org\/10.1517\/14656566.2012.662220","journal-title":"Expert Opin Pharmacother"},{"key":"4520_CR14","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894\u20132903","journal-title":"Circulation"},{"key":"4520_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1586\/14779072.4.3.293","volume":"4","author":"AR Hemnes","year":"2006","unstructured":"Hemnes AR, Champion HC (2006) Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Rev Cardiovasc Ther 4:293\u2013300. https:\/\/doi.org\/10.1586\/14779072.4.3.293[doi]","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"4520_CR16","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1021\/jm0300577","volume":"46","author":"A Daugan","year":"2003","unstructured":"Daugan A, Grondin P, Ruault C, Monnier Le, de Gouville AC, Coste H, Linget JM, Kirilovsky J, Hyafil F, Labaudiniere R (2003) The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1\u2019,2\u2019:1,6]pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem 46:4533\u20134542. https:\/\/doi.org\/10.1021\/jm0300577","journal-title":"J Med Chem"},{"key":"4520_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","volume":"147","author":"A Das","year":"2015","unstructured":"Das A, Durrant D, Salloum FN, Xi L, Kukreja RC (2015) PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther 147:12\u201321","journal-title":"Pharmacol Ther"},{"key":"4520_CR18","doi-asserted-by":"publisher","first-page":"12944","DOI":"10.1074\/jbc.M404706200","volume":"280","author":"A Das","year":"2005","unstructured":"Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944\u201312955","journal-title":"J Biol Chem"},{"key":"4520_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1161\/01.RES.0000066853.09821.98","volume":"92","author":"F Salloum","year":"2003","unstructured":"Salloum F, Yin C, Xi L, Kukreja RC (2003) Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595\u2013597","journal-title":"Circ Res"},{"key":"4520_CR20","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1161\/CIRCULATIONAHA.108.843979","volume":"120","author":"FN Salloum","year":"2009","unstructured":"Salloum FN, Chau VQ, Hoke NN, Abbate A, Varma A, Ockaili RA, Toldo S, Kukreja RC (2009) Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia\/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation 120:S31\u2013S36","journal-title":"Circulation"},{"key":"4520_CR21","doi-asserted-by":"publisher","first-page":"H1236","DOI":"10.1152\/ajpheart.00100.2009","volume":"296","author":"A Das","year":"2009","unstructured":"Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC (2009) ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296:H1236\u2013H1243","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4520_CR22","doi-asserted-by":"publisher","first-page":"H1263","DOI":"10.1152\/ajpheart.00324.2002","volume":"283","author":"R Ockaili","year":"2002","unstructured":"Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263\u2013H1269","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4520_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035739","author":"E Rentoukas","year":"2012","unstructured":"Rentoukas E, Tsarouhas K, Kaplanis I, Korou E, Nikolaou M, Marathonitis G, Kokkinou S, Haliassos A, Mamalaki A, Kouretas D, Tsitsimpikou C (2012) Connection between telomerase activity in PBMC and markers of inflammation and endothelial dysfunction in patients with metabolic syndrome. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0035739","journal-title":"PLoS ONE"},{"key":"4520_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/nyas.12030","volume":"1281","author":"R Weiss","year":"2013","unstructured":"Weiss R, Bremer AA, Lustig RH (2013) What is metabolic syndrome, and why are children getting it? Ann N Y Acad Sci 1281:123\u2013140. https:\/\/doi.org\/10.1111\/nyas.12030","journal-title":"Ann N Y Acad Sci"},{"key":"4520_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.trsl.2017.01.001","volume":"183","author":"JD Tune","year":"2017","unstructured":"Tune JD, Goodwill AG, Sassoon DJ, Mather KJ (2017) Cardiovascular consequences of metabolic syndrome. Transl Res 183:57\u201370. https:\/\/doi.org\/10.1016\/j.trsl.2017.01.001","journal-title":"Transl Res"},{"key":"4520_CR26","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2337\/db06-0883","volume":"56","author":"JE Ayala","year":"2007","unstructured":"Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH (2007) Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56:1025\u20131033. https:\/\/doi.org\/10.2337\/db06-0883","journal-title":"Diabetes"},{"key":"4520_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223914","author":"Y Doghri","year":"2019","unstructured":"Doghri Y, Chetaneau F, Rhimi M, Kriaa A, Lalanne V, Thorin C, Maguin E, Mallem MY, Desfontis JC (2019) Sildenafil citrate long-term treatment effects on cardiovascular reactivity in a SHR experimental model of metabolic syndrome. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0223914","journal-title":"PLoS ONE"},{"key":"4520_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.eururo.2005.12.055","volume":"49","author":"F Montorsi","year":"2006","unstructured":"Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL (2006) Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur Urol 49:979\u2013986. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.055","journal-title":"Eur Urol"},{"key":"4520_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.amjmed.2012.08.015","volume":"126","author":"BG Schwartz","year":"2013","unstructured":"Schwartz BG, Jackson G, Stecher VJ, Campoli-Richards DM, Kloner RA (2013) Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. Am J Med 126:192\u2013199. https:\/\/doi.org\/10.1016\/j.amjmed.2012.08.015","journal-title":"Am J Med"},{"key":"4520_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/dmrr.921","volume":"25","author":"A Stirban","year":"2009","unstructured":"Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ, Ziegler D (2009) Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev 25:136\u2013143. https:\/\/doi.org\/10.1002\/dmrr.921","journal-title":"Diabetes Metab Res Rev"},{"key":"4520_CR31","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2007.10.069","volume":"51","author":"C Gazzaruso","year":"2008","unstructured":"Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, Salvucci F, Valenti C, Giustina A, Garzaniti A (2008) Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 51:2040\u20132044. https:\/\/doi.org\/10.1016\/j.jacc.2007.10.069","journal-title":"J Am Coll Cardiol"},{"key":"4520_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/sj.ijir.3901513","volume":"19","author":"A Aversa","year":"2007","unstructured":"Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G (2007) Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 19:200\u2013207. https:\/\/doi.org\/10.1038\/sj.ijir.3901513","journal-title":"Int J Impot Res"},{"key":"4520_CR33","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2337\/diacare.25.8.1336","volume":"25","author":"C Desouza","year":"2002","unstructured":"Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25:1336\u20131339. https:\/\/doi.org\/10.2337\/diacare.25.8.1336","journal-title":"Diabetes Care"},{"key":"4520_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-019-06851-7","volume":"33","author":"Z Cai","year":"2019","unstructured":"Cai Z, Zhang J, Li H (2019) Two birds with one stone: regular use of PDE5 inhibitors for treating male patients with erectile dysfunction and cardiovascular diseases. Cardiovasc Drugs Ther 33:119\u2013128. https:\/\/doi.org\/10.1007\/s10557-019-06851-7","journal-title":"Cardiovasc Drugs Ther"},{"key":"4520_CR35","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","volume":"104","author":"DC Hutchings","year":"2018","unstructured":"Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (2018) Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart 104:1244\u20131250. https:\/\/doi.org\/10.1136\/heartjnl-2017-312865","journal-title":"Heart"},{"key":"4520_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40618-015-0339-y","volume":"39","author":"R Pofi","year":"2016","unstructured":"Pofi R, Gianfrilli D, Badagliacca R, Di Dato C, Venneri MA, Giannetta E (2016) Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): how do they work? J Endocrinol Invest 39:131\u2013142. https:\/\/doi.org\/10.1007\/s40618-015-0339-y","journal-title":"J Endocrinol Invest"},{"key":"4520_CR37","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.yjmcc.2012.10.001","volume":"53","author":"T Itoh","year":"2012","unstructured":"Itoh T, Kouzu H, Miki T, Tanno M, Kuno A, Sato T, Sunaga D, Murase H, Miura T (2012) Cytoprotective regulation of the mitochondrial permeability transition pore is impaired in type 2 diabetic Goto-Kakizaki rat hearts. J Mol Cell Cardiol 53:870\u2013879. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.10.001","journal-title":"J Mol Cell Cardiol"},{"key":"4520_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1475-2840-11-89","volume":"11","author":"G Van der Mieren","year":"2012","unstructured":"Van der Mieren G, Nevelsteen I, Vanderper A, Oosterlinck W, Flameng W, Herijgers P (2012) Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury. Cardiovasc Diabetol 11:89. https:\/\/doi.org\/10.1186\/1475-2840-11-89","journal-title":"Cardiovasc Diabetol"},{"key":"4520_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045243","author":"A Varma","year":"2012","unstructured":"Varma A, Das A, Hoke NN, Durrant DE, Salloum FN, Kukreja RC (2012) Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0045243","journal-title":"PLoS ONE"},{"key":"4520_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11010-020-03710-0","volume":"468","author":"S Koka","year":"2020","unstructured":"Koka S, Xi L, Kukreja RC (2020) Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide. Mol Cell Biochem 468:47\u201358. https:\/\/doi.org\/10.1007\/s11010-020-03710-0","journal-title":"Mol Cell Biochem"},{"key":"4520_CR41","doi-asserted-by":"publisher","first-page":"H1558","DOI":"10.1152\/ajpheart.00865.2013","volume":"306","author":"S Koka","year":"2014","unstructured":"Koka S, Aluri HS, Xi L, Lesnefsky EJ, Kukreja RC (2014) Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO\/SIRT1\/PGC-1alpha signaling. Am J Physiol Heart Circ Physiol 306:H1558\u2013H1568. https:\/\/doi.org\/10.1152\/ajpheart.00865.2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4520_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2013.01.031","volume":"60","author":"S Koka","year":"2013","unstructured":"Koka S, Das A, Salloum FN, Kukreja RC (2013) Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia\/reperfusion injury in type 2 diabetic mice. Free Radic Biol Med 60:80\u201388","journal-title":"Free Radic Biol Med"},{"key":"4520_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00395-012-0249-5","volume":"107","author":"S Koka","year":"2012","unstructured":"Koka S, Xi L, Kukreja RC (2012) Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. Basic Res Cardiol 107:249. https:\/\/doi.org\/10.1007\/s00395-012-0249-5","journal-title":"Basic Res Cardiol"},{"key":"4520_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012273","author":"TM West","year":"2019","unstructured":"West TM, Wang Q, Deng B, Zhang Y, Barbagallo F, Reddy GR, Chen D, Phan KS, Xu B, Isidori A, Xiang YK (2019) Phosphodiesterase 5 associates with beta2 adrenergic receptor to modulate cardiac function in type 2 diabetic hearts. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.119.012273","journal-title":"J Am Heart Assoc"},{"key":"4520_CR45","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","volume":"125","author":"E Giannetta","year":"2012","unstructured":"Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F, Lenzi A (2012) Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125:2323\u20132333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.063412","journal-title":"Circulation"},{"issue":"649","key":"4520_CR46","doi-asserted-by":"publisher","first-page":"eabl8503","DOI":"10.1126\/scitranslmed.abl8503","volume":"14","author":"R Pofi","year":"2022","unstructured":"Pofi R, Giannetta E, Feola T, Galea N, Barbagallo F, Campolo F, Badagliacca R, Barbano B, Ciolina F, Defeudis G, Filardi T, Sesti F, Minnetti M, Vizza CD, Pasqualetti P, Caboni P, Carbone I, Francone M, Catalano C, Pozzilli P, Lenzi A, Venneri MA, Gianfrilli D, Isidori AM (2022) Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Sci Transl Med 14(649):eabl8503. https:\/\/doi.org\/10.1126\/scitranslmed.abl8503","journal-title":"Sci Transl Med"},{"key":"4520_CR47","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","volume":"38","author":"D Plantone","year":"2018","unstructured":"Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38:653\u2013671. https:\/\/doi.org\/10.1007\/s40261-018-0656-y","journal-title":"Clin Drug Investig"},{"key":"4520_CR48","first-page":"6","volume":"44","author":"RJ Anderson","year":"1995","unstructured":"Anderson RJ (1995) Hydroxychloroquine therapy in rheumatic diseases. Bull Rheum Dis 44:6\u20137","journal-title":"Bull Rheum Dis"},{"key":"4520_CR49","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1136\/ard.51.12.1318","volume":"51","author":"EF Morand","year":"1992","unstructured":"Morand EF, McCloud PI, Littlejohn GO (1992) Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 51:1318\u20131321","journal-title":"Ann Rheum Dis"},{"key":"4520_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fonc.2018.00335","volume":"8","author":"P Weyerhauser","year":"2018","unstructured":"Weyerhauser P, Kantelhardt SR, Kim EL (2018) Re-purposing chloroquine for glioblastoma: potential merits and confounding variables. Front Oncol 8:335. https:\/\/doi.org\/10.3389\/fonc.2018.00335","journal-title":"Front Oncol"},{"key":"4520_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.bbrc.2013.05.047","volume":"435","author":"MJ Halaby","year":"2013","unstructured":"Halaby MJ, Kastein BK, Yang DQ (2013) Chloroquine stimulates glucose uptake and glycogen synthase in muscle cells through activation of Akt. Biochem Biophys Res Commun 435:708\u2013713","journal-title":"Biochem Biophys Res Commun"},{"key":"4520_CR52","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2337\/diab.33.12.1133","volume":"33","author":"BR Blazar","year":"1984","unstructured":"Blazar BR, Whitley CB, Kitabchi AE, Tsai MY, Santiago J, White N, Stentz FB, Brown DM (1984) In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 33:1133\u20131137","journal-title":"Diabetes"},{"key":"4520_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2042018814547204","volume":"5","author":"MP Hage","year":"2014","unstructured":"Hage MP, Al-Badri MR, Azar ST (2014) A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab 5:77\u201385","journal-title":"Ther Adv Endocrinol Metab"},{"key":"4520_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0026-0495(93)90096-7","volume":"42","author":"JK Powrie","year":"1993","unstructured":"Powrie JK, Shojaee-Moradie F, Watts GF, Smith GD, Sonksen PH, Jones RH (1993) Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism 42:415\u2013419","journal-title":"Metabolism"},{"key":"4520_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/0253-7613.55213","volume":"41","author":"A Pareek","year":"2009","unstructured":"Pareek A, Yeole PG, Tenpe CR, Chandurkar N, Payghan R (2009) Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats. Indian J Pharmacol 41:125\u2013128. https:\/\/doi.org\/10.4103\/0253-7613.55213","journal-title":"Indian J Pharmacol"},{"key":"4520_CR56","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/acr.22285","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Garg R, Lu B, Todd DJ, Mercer E, Norton T, Massarotti E (2014) Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken) 66:1246\u20131251","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4520_CR57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/RHU.0b013e318214b6b5","volume":"17","author":"A Bili","year":"2011","unstructured":"Bili A, Sartorius JA, Kirchner HL, Morris SJ, Ledwich LJ, Antohe JL, Dancea S, Newman ED, Wasko MC (2011) Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 17:115\u2013120. https:\/\/doi.org\/10.1097\/RHU.0b013e318214b6b5","journal-title":"J Clin Rheumatol"},{"key":"4520_CR58","doi-asserted-by":"publisher","first-page":"678","DOI":"10.7326\/0003-4819-112-9-678","volume":"112","author":"A Quatraro","year":"1990","unstructured":"Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, Giugliano D (1990) Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 112:678\u2013681. https:\/\/doi.org\/10.7326\/0003-4819-112-9-678","journal-title":"Ann Intern Med"},{"key":"4520_CR59","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0168-8227(01)00325-4","volume":"55","author":"HC Gerstein","year":"2002","unstructured":"Gerstein HC, Thorpe KE, Taylor DW, Haynes RB (2002) The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas: a randomized trial. Diabetes Res Clin Pract 55:209\u2013219","journal-title":"Diabetes Res Clin Pract"},{"key":"4520_CR60","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1007\/s00125-015-3689-2","volume":"58","author":"MC Wasko","year":"2015","unstructured":"Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG (2015) Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia 58:2336\u20132343","journal-title":"Diabetologia"},{"key":"4520_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143771","author":"L Bourke","year":"2015","unstructured":"Bourke L, McCormick J, Taylor V, Pericleous C, Blanchet B, Costedoat-Chalumeau N, Stuckey D, Lythgoe MF, Stephanou A, Ioannou Y (2015) Hydroxychloroquine protects against cardiac ischaemia\/reperfusion injury in vivo via enhancement of ERK1\/2 phosphorylation. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0143771","journal-title":"PLoS ONE"},{"key":"4520_CR62","doi-asserted-by":"publisher","first-page":"A10246","DOI":"10.1161\/circ.132.suppl_3.10246","volume":"132","author":"F Yang","year":"2015","unstructured":"Yang F, Yin C, Xi L, Kukreja RC (2015) Hydroxychloroquine pretreatment reduces myocardial ischemia-reperfusion injury: role of cardiac extracellular-signal-regulated kinase 5 and autophagy. Circulation 132:A10246\u2013A10246. https:\/\/doi.org\/10.1161\/circ.132.suppl_3.10246","journal-title":"Circulation"},{"key":"4520_CR63","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.111.300483","volume":"112","author":"L Long","year":"2013","unstructured":"Long L, Yang X, Southwood M, Lu J, Marciniak SJ, Dunmore BJ, Morrell NW (2013) Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ Res 112:1159\u20131170","journal-title":"Circ Res"},{"key":"4520_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1124\/jpet.116.239087","volume":"361","author":"R Wang","year":"2017","unstructured":"Wang R, Xi L, Kukreja RC (2017) PDE5 inhibitor tadalafil and hydroxychloroquine cotreatment provides synergistic protection against type 2 diabetes and myocardial infarction in mice. J Pharmacol Exp Ther 361:29\u201338","journal-title":"J Pharmacol Exp Ther"},{"key":"4520_CR65","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2337\/dc08-1862","volume":"32","author":"KD Hill","year":"2009","unstructured":"Hill KD, Eckhauser AW, Marney A, Brown NJ (2009) Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome. Diabetes Care 32:857\u2013859","journal-title":"Diabetes Care"},{"key":"4520_CR66","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrm2234","volume":"8","author":"SJ Russell","year":"2007","unstructured":"Russell SJ, Kahn CR (2007) Endocrine regulation of ageing. Nat Rev Mol Cell Biol 8:681\u2013691. https:\/\/doi.org\/10.1038\/nrm2234","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4520_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJM198707163170303","volume":"317","author":"HP Guler","year":"1987","unstructured":"Guler HP, Zapf J, Froesch ER (1987) Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137\u2013140. https:\/\/doi.org\/10.1056\/NEJM198707163170303","journal-title":"N Engl J Med"},{"key":"4520_CR68","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1073\/pnas.92.17.8031","volume":"92","author":"M Buerke","year":"1995","unstructured":"Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM (1995) Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A 92:8031\u20138035. https:\/\/doi.org\/10.1073\/pnas.92.17.8031","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4520_CR69","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1161\/hh2401.101385","volume":"89","author":"AK Jonassen","year":"2001","unstructured":"Jonassen AK, Sack MN, Mjos OD, Yellon DM (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191\u20131198. https:\/\/doi.org\/10.1161\/hh2401.101385","journal-title":"Circ Res"},{"key":"4520_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.surg.2009.03.028","volume":"146","author":"A Oates","year":"2009","unstructured":"Oates A, Nubani R, Smiley J, Kistler L, Hughey S, Theiss P, Perez-Tamayo RA, Eiferman D, Lonchyna V, Higgins RS (2009) Myocardial protection of insulin and potassium in a porcine ischemia-reperfusion model. Surgery 146:23\u201330","journal-title":"Surgery"},{"key":"4520_CR71","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0735-1097(03)00164-5","volume":"41","author":"MN Sack","year":"2003","unstructured":"Sack MN, Yellon DM (2003) Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 41:1404\u20131407","journal-title":"J Am Coll Cardiol"},{"key":"4520_CR72","doi-asserted-by":"publisher","first-page":"E871","DOI":"10.1152\/ajpendo.00623.2009","volume":"298","author":"L Ji","year":"2010","unstructured":"Ji L, Fu F, Zhang L, Liu W, Cai X, Zhang L, Zheng Q, Zhang H, Gao F (2010) Insulin attenuates myocardial ischemia\/reperfusion injury via reducing oxidative\/nitrative stress. Am J Physiol Endocrinol Metab 298:E871\u2013E880","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4520_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.freeradbiomed.2014.06.023","volume":"74","author":"M Ribeiro","year":"2014","unstructured":"Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC (2014) Insulin and IGF-1 improve mitochondrial function in a PI-3K\/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington\u2019s disease knock-in striatal cells. Free Radic Biol Med 74:129\u2013144","journal-title":"Free Radic Biol Med"},{"key":"4520_CR74","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1586\/14779072.6.8.1135","volume":"6","author":"A Abbas","year":"2008","unstructured":"Abbas A, Grant PJ, Kearney MT (2008) Role of IGF-1 in glucose regulation and cardiovascular disease. Expert Rev Cardiovasc Ther 6:1135\u20131149. https:\/\/doi.org\/10.1586\/14779072.6.8.1135","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"4520_CR75","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/art.1780050507","volume":"5","author":"EB Hamilton","year":"1962","unstructured":"Hamilton EB, Scott JT (1962) Hydroxychloroquine sulfate (\u201cplaguenil\u201d) in treatment of rheumatoid arthritis. Arthritis Rheum 5:502\u2013512. https:\/\/doi.org\/10.1002\/art.1780050507","journal-title":"Arthritis Rheum"},{"key":"4520_CR76","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.2174\/1381612826666200707132920","volume":"26","author":"GP Martinez","year":"2020","unstructured":"Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR (2020) The role of chloroquine and hydroxychloroquine in immune regulation and diseases. Curr Pharm Des 26:4467\u20134485. https:\/\/doi.org\/10.2174\/1381612826666200707132920","journal-title":"Curr Pharm Des"},{"key":"4520_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2016.06.010","volume":"74","author":"L Durcan","year":"2016","unstructured":"Durcan L, Petri M (2016) Immunomodulators in SLE: clinical evidence and immunologic actions. J Autoimmun 74:73\u201384. https:\/\/doi.org\/10.1016\/j.jaut.2016.06.010","journal-title":"J Autoimmun"},{"key":"4520_CR78","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-018-0378-3","volume":"9","author":"TT Tang","year":"2018","unstructured":"Tang TT, Lv LL, Pan MM, Wen Y, Wang B, Li ZL, Wu M, Wang FM, Crowley SD, Liu BC (2018) Hydroxychloroquine attenuates renal ischemia\/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death Dis 9:351. https:\/\/doi.org\/10.1038\/s41419-018-0378-3","journal-title":"Cell Death Dis"},{"key":"4520_CR79","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrendo.2009.62","volume":"5","author":"B Feve","year":"2009","unstructured":"Feve B, Bastard JP (2009) The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 5:305\u2013311. https:\/\/doi.org\/10.1038\/nrendo.2009.62","journal-title":"Nat Rev Endocrinol"},{"key":"4520_CR80","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860\u2013867. https:\/\/doi.org\/10.1038\/nature05485","journal-title":"Nature"},{"key":"4520_CR81","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","volume":"223","author":"WP Arend","year":"2008","unstructured":"Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20\u201338. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00624.x","journal-title":"Immunol Rev"},{"key":"4520_CR82","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/eji.200940207","volume":"40","author":"SL Cassel","year":"2010","unstructured":"Cassel SL, Sutterwala FS (2010) Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol 40:607\u2013611. https:\/\/doi.org\/10.1002\/eji.200940207","journal-title":"Eur J Immunol"},{"key":"4520_CR83","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/039463200902200208","volume":"22","author":"Y Yin","year":"2009","unstructured":"Yin Y, Yan Y, Jiang X, Mai J, Chen NC, Wang H, Yang XF (2009) Inflammasomes are differentially expressed in cardiovascular and other tissues. Int J Immunopathol Pharmacol 22:311\u2013322. https:\/\/doi.org\/10.1177\/039463200902200208","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4520_CR84","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/eji.200940185","volume":"40","author":"V Hornung","year":"2010","unstructured":"Hornung V, Latz E (2010) Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol 40:620\u2013623. https:\/\/doi.org\/10.1002\/eji.200940185[doi]","journal-title":"Eur J Immunol"},{"key":"4520_CR85","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature02664","volume":"430","author":"S Mariathasan","year":"2004","unstructured":"Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, Roose-Girma M, Erickson S, Dixit VM (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430:213\u2013218. https:\/\/doi.org\/10.1038\/nature02664[doi];nature02664[pii]","journal-title":"Nature"},{"key":"4520_CR86","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/ni.1960","volume":"11","author":"EA Miao","year":"2010","unstructured":"Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, Warren SE, Wewers MD, Aderem A (2010) Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 11:1136\u20131142","journal-title":"Nat Immunol"},{"key":"4520_CR87","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nri2725","volume":"10","author":"J Tschopp","year":"2010","unstructured":"Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10:210\u2013215","journal-title":"Nat Rev Immunol"},{"key":"4520_CR88","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0022-2828(03)00113-5","volume":"35","author":"S Frantz","year":"2003","unstructured":"Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R, Tracey D, Allen H, Lee RT, Kelly RA (2003) Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 35:685\u2013694","journal-title":"J Mol Cell Cardiol"},{"key":"4520_CR89","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/01.RES.0000260203.55077.61","volume":"100","author":"S Merkle","year":"2007","unstructured":"Merkle S, Frantz S, Schon MP, Bauersachs J, Buitrago M, Frost RJ, Schmitteckert EM, Lohse MJ, Engelhardt S (2007) A role for caspase-1 in heart failure. Circ Res 100:645\u2013653","journal-title":"Circ Res"},{"key":"4520_CR90","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cmet.2010.11.011","volume":"12","author":"R Stienstra","year":"2010","unstructured":"Stienstra R, Joosten LA, Koenen T, van TB, van Diepen JA, van den Berg SA, Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Muller M, van den Berg WB, van RN, Wabitsch M, Kullberg BJ, van der Meer JW, Kanneganti T, Tack CJ, Netea MG (2010) The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 12:593\u2013605","journal-title":"Cell Metab"},{"key":"4520_CR91","doi-asserted-by":"publisher","first-page":"15324","DOI":"10.1073\/pnas.1100255108","volume":"108","author":"R Stienstra","year":"2011","unstructured":"Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, Neale GA, Hooiveld GJ, Hijmans A, Vroegrijk I, van den Berg S, Romijn J, Rensen PC, Joosten LA, Netea MG, Kanneganti TD (2011) Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A 108:15324\u201315329","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4520_CR92","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17:179\u2013188","journal-title":"Nat Med"},{"key":"4520_CR93","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/ni.2022","volume":"12","author":"H Wen","year":"2011","unstructured":"Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP (2011) Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12:408\u2013415","journal-title":"Nat Immunol"},{"key":"4520_CR94","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ni.1831","volume":"11","author":"R Zhou","year":"2010","unstructured":"Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11:136\u2013140","journal-title":"Nat Immunol"},{"key":"4520_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186790","author":"A Samidurai","year":"2020","unstructured":"Samidurai A, Das A (2020) Cardiovascular complications associated with COVID-19 and potential therapeutic strategies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21186790","journal-title":"Int J Mol Sci"},{"key":"4520_CR96","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.dsx.2020.07.005","volume":"14","author":"N Zaki","year":"2020","unstructured":"Zaki N, Alashwal H, Ibrahim S (2020) Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: a systematic review. Diabetes Metab Syndr 14:1133\u20131142. https:\/\/doi.org\/10.1016\/j.dsx.2020.07.005","journal-title":"Diabetes Metab Syndr"},{"key":"4520_CR97","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1007\/s00125-020-05209-1","volume":"63","author":"S Wang","year":"2020","unstructured":"Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, Xu J, Wu F, Duan L, Yin Z, Luo H, Xiong N, Xu M, Zeng T, Jin Y (2020) Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 63:2102\u20132111. https:\/\/doi.org\/10.1007\/s00125-020-05209-1","journal-title":"Diabetologia"},{"key":"4520_CR98","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S2213-8587(20)30271-0","volume":"8","author":"N Holman","year":"2020","unstructured":"Holman N, Knighton P, Kar P, O\u2019Keefe J, Curley M, Weaver A, Barron E, Bakhai C, Khunti K, Wareham NJ, Sattar N, Young B, Valabhji J (2020) Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 8:823\u2013833. https:\/\/doi.org\/10.1016\/S2213-8587(20)30271-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4520_CR99","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1530\/VB-20-0017","volume":"3","author":"R Giordo","year":"2021","unstructured":"Giordo R, Paliogiannis P, Mangoni AA, Pintus G (2021) SARS-CoV-2 and endothelial cell interaction in COVID-19: molecular perspectives. Vasc Biol 3:R15\u2013R23. https:\/\/doi.org\/10.1530\/VB-20-0017","journal-title":"Vasc Biol"},{"key":"4520_CR100","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41401-020-00554-8","volume":"41","author":"ZO Serebrovska","year":"2020","unstructured":"Serebrovska ZO, Chong EY, Serebrovska TV, Tumanovska LV, Xi L (2020) Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets. Acta Pharmacol Sin 41:1539\u20131546. https:\/\/doi.org\/10.1038\/s41401-020-00554-8","journal-title":"Acta Pharmacol Sin"},{"key":"4520_CR101","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/ijpvm.IJPVM_258_20","volume":"11","author":"L Mario","year":"2020","unstructured":"Mario L, Roberto M, Marta L, Teresa CM, Laura M (2020) Hypothesis of COVID-19 therapy with sildenafil. Int J Prev Med 11:76. https:\/\/doi.org\/10.4103\/ijpvm.IJPVM_258_20","journal-title":"Int J Prev Med"},{"key":"4520_CR102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.brainres.2015.09.008","volume":"1627","author":"AK Nunes","year":"2015","unstructured":"Nunes AK, Raposo C, Rocha SW, Barbosa KP, Luna RL, da Cruz-Hofling MA, Peixoto CA (2015) Involvement of AMPK, IKbetaalpha-NFkappaB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model. Brain Res 1627:119\u2013133. https:\/\/doi.org\/10.1016\/j.brainres.2015.09.008","journal-title":"Brain Res"},{"key":"4520_CR103","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2217\/fca-2020-0201","volume":"17","author":"M Shirvaliloo","year":"2021","unstructured":"Shirvaliloo M (2021) Targeting the SARS-CoV-2 3CL(pro) and NO\/cGMP\/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors. Future Cardiol 17:765\u2013768. https:\/\/doi.org\/10.2217\/fca-2020-0201","journal-title":"Future Cardiol"},{"key":"4520_CR104","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY, Group HUSS","year":"2004","unstructured":"Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY, Group HUSS (2004) Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252\u2013256. https:\/\/doi.org\/10.1136\/thorax.2003.012658","journal-title":"Thorax"},{"key":"4520_CR105","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293. https:\/\/doi.org\/10.1038\/s41586-020-2223-y","journal-title":"Nature"},{"key":"4520_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/computation8020053","author":"Z Qiao","year":"2020","unstructured":"Qiao Z, Zhang H, Ji HF, Chen Q (2020) Computational view toward the inhibition of SARS-CoV-2 spike glycoprotein and the 3CL protease. Computation (Basel). https:\/\/doi.org\/10.3390\/computation8020053","journal-title":"Computation (Basel)"},{"key":"4520_CR107","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/s41401-020-0438-y","volume":"41","author":"H Li","year":"2020","unstructured":"Li H, Yang L, Liu FF, Ma XN, He PL, Tang W, Tong XK, Zuo JP (2020) Overview of therapeutic drug research for COVID-19 in China. Acta Pharmacol Sin 41:1133\u20131140. https:\/\/doi.org\/10.1038\/s41401-020-0438-y","journal-title":"Acta Pharmacol Sin"},{"key":"4520_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105960","author":"J Fantini","year":"2020","unstructured":"Fantini J, Di Scala C, Chahinian H, Yahi N (2020) Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105960","journal-title":"Int J Antimicrob Agents"},{"key":"4520_CR109","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/jmv.26583","volume":"93","author":"CK Yuen","year":"2021","unstructured":"Yuen CK, Wong WM, Mak LF, Wang X, Chu H, Yuen KY, Kok KH (2021) Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase. J Med Virol 93:2076\u20132083. https:\/\/doi.org\/10.1002\/jmv.26583","journal-title":"J Med Virol"},{"key":"4520_CR110","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1080\/15548627.2020.1779467","volume":"16","author":"SR Bonam","year":"2020","unstructured":"Bonam SR, Muller S, Bayry J, Klionsky DJ (2020) Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. Autophagy 16:2260\u20132266. https:\/\/doi.org\/10.1080\/15548627.2020.1779467","journal-title":"Autophagy"},{"key":"4520_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. https:\/\/doi.org\/10.1038\/s41421-020-0156-0","journal-title":"Cell Discov"},{"key":"4520_CR112","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.7326\/M21-0653","volume":"174","author":"A Barratt-Due","year":"2021","unstructured":"Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kasine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Kildal AB, Berg A, Johannessen A, Heggelund L, Dahl TB, Skara KH, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR, Olsen RB, Tholin B, Ystrom CM, Skei NV, Tran T, Dudman S, Andersen JT, Hannula R, Dalgard O, Finbraten AK, Tonby K, Blomberg B, Aballi S, Fladeby C, Steffensen A, Muller F, Dyrhol-Riise AM, Troseid M, Aukrust P, trial NO-S (2021) Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial. Ann Intern Med 174:1261\u20131269. https:\/\/doi.org\/10.7326\/M21-0653","journal-title":"Ann Intern Med"},{"key":"4520_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101906","author":"SN Szente Fonseca","year":"2020","unstructured":"Szente Fonseca SN, de Queiroz SA, Wolkoff AG, Moreira MS, Pinto BC, Valente Takeda CF, Reboucas E, Vasconcellos Abdon AP, Nascimento ALA, Risch HA (2020) Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: comparative analysis. Travel Med Infect Dis. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101906","journal-title":"Travel Med Infect Dis"},{"key":"4520_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106020","author":"J Fantini","year":"2020","unstructured":"Fantini J, Chahinian H, Yahi N (2020) Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106020","journal-title":"Int J Antimicrob Agents"},{"key":"4520_CR115","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/15563650.2020.1817479","volume":"59","author":"C Doyno","year":"2021","unstructured":"Doyno C, Sobieraj DM, Baker WL (2021) Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin Toxicol (Phila) 59:12\u201323. https:\/\/doi.org\/10.1080\/15563650.2020.1817479","journal-title":"Clin Toxicol (Phila)"},{"key":"4520_CR116","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2048872612471215","volume":"2","author":"E Joyce","year":"2013","unstructured":"Joyce E, Fabre A, Mahon N (2013) Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care 2:77\u201383. https:\/\/doi.org\/10.1177\/2048872612471215","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"4520_CR117","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/cts.12883","volume":"14","author":"S Romani","year":"2021","unstructured":"Romani S, Gerard A, Fresse A, Viard D, Van-Obberghen E, Micallef J, Rocher F, Drici MD, French Pharmacovigilance N (2021) Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic. Clin Transl Sci 14:163\u2013169. https:\/\/doi.org\/10.1111\/cts.12883","journal-title":"Clin Transl Sci"},{"key":"4520_CR118","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/s0735-1097(85)80387-9","volume":"5","author":"DM Mirvis","year":"1985","unstructured":"Mirvis DM (1985) Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction. J Am Coll Cardiol 5:625\u2013631. https:\/\/doi.org\/10.1016\/s0735-1097(85)80387-9","journal-title":"J Am Coll Cardiol"},{"key":"4520_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1968","author":"SS Bun","year":"2020","unstructured":"Bun SS, Taghji P, Courjon J, Squara F, Scarlatti D, Theodore G, Baudouy D, Sartre B, Labbaoui M, Dellamonica J, Doyen D, Marquette CH, Levraut J, Esnault V, Bun SS, Ferrari E (2020) QT interval prolongation under hydroxychloroquine\/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.1968","journal-title":"Clin Pharmacol Ther"},{"key":"4520_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2020.06.029","author":"M Hooks","year":"2020","unstructured":"Hooks M, Bart B, Vardeny O, Westanmo A, Adabag S (2020) Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm. https:\/\/doi.org\/10.1016\/j.hrthm.2020.06.029","journal-title":"Heart Rhythm"},{"key":"4520_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.04.016","author":"A Sarayani","year":"2020","unstructured":"Sarayani A, Cicali B, Henriksen CH, Brown JD (2020) Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. https:\/\/doi.org\/10.1016\/j.sapharm.2020.04.016","journal-title":"Res Social Adm Pharm"},{"key":"4520_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2020.05.030","author":"I Uzelac","year":"2020","unstructured":"Uzelac I, Iravanian S, Ashikaga H, Bhatia NK, Herndon C, Kaboudian A, Gumbart JC, Cherry EM, Fenton FH (2020) Fatal arrhythmias: another reason why doctors remain cautious about chloroquine\/hydroxychloroquine for treating COVID-19. Heart Rhythm. https:\/\/doi.org\/10.1016\/j.hrthm.2020.05.030","journal-title":"Heart Rhythm"},{"key":"4520_CR123","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1365-2796.2002.00955.x","volume":"251","author":"M Veglio","year":"2002","unstructured":"Veglio M, Bruno G, Borra M, Macchia G, Bargero G, D\u2019Errico N, Pagano GF, Cavallo-Perin P (2002) Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med 251:317\u2013324. https:\/\/doi.org\/10.1046\/j.1365-2796.2002.00955.x","journal-title":"J Intern Med"},{"key":"4520_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.06.099","author":"S Arshad","year":"2020","unstructured":"Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O\u2019Neill W, Zervos M, Henry Ford C-TF (2020) Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. https:\/\/doi.org\/10.1016\/j.ijid.2020.06.099","journal-title":"Int J Infect Dis"},{"key":"4520_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101791","author":"JC Lagier","year":"2020","unstructured":"Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, Honore S, Gaubert JY, Fournier PE, Tissot-Dupont H, Chabriere E, Stein A, Deharo JC, Fenollar F, Rolain JM, Obadia Y, Jacquier A, La Scola B, Brouqui P, Drancourt M, Parola P, Raoult D, force IC-T, (2020) Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine\/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101791","journal-title":"Travel Med Infect Dis"},{"key":"4520_CR126","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1732-2","author":"B Yu","year":"2020","unstructured":"Yu B, Li C, Chen P, Zhou N, Wang L, Li J, Jiang H, Wang DW (2020) Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. https:\/\/doi.org\/10.1007\/s11427-020-1732-2","journal-title":"Sci China Life Sci"},{"key":"4520_CR127","doi-asserted-by":"publisher","unstructured":"Covid R, Treatments C, COVID-19 RISK and Treatments (CORIST) Collaboration (2020) Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study. Eur J Intern Med 82:38\u201347. https:\/\/doi.org\/10.1016\/j.ejim.2020.08.019","DOI":"10.1016\/j.ejim.2020.08.019"},{"key":"4520_CR128","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2020.11.018","volume":"82","author":"PW Horby","year":"2020","unstructured":"Horby PW, Emberson JR (2020) Hydroxychloroquine for COVID-19: balancing contrasting claims. Eur J Intern Med 82:25\u201326. https:\/\/doi.org\/10.1016\/j.ejim.2020.11.018","journal-title":"Eur J Intern Med"},{"key":"4520_CR129","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41401-020-00519-x","volume":"41","author":"XL Zhang","year":"2020","unstructured":"Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD (2020) Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta Pharmacol Sin 41:1377\u20131386. https:\/\/doi.org\/10.1038\/s41401-020-00519-x","journal-title":"Acta Pharmacol Sin"},{"key":"4520_CR130","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bjp.0705658","volume":"141","author":"O Nagy","year":"2004","unstructured":"Nagy O, Hajnal A, Parratt JR, Vegh A (2004) Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol 141:549\u2013551. https:\/\/doi.org\/10.1038\/sj.bjp.0705658","journal-title":"Br J Pharmacol"},{"key":"4520_CR131","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCRESAHA.121.318473","volume":"129","author":"DC Hutchings","year":"2021","unstructured":"Hutchings DC, Pearman CM, Madders GWP, Woods LS, Eisner DA, Dibb KM, Trafford AW (2021) PDE5 inhibition suppresses ventricular arrhythmias by reducing SR Ca(2+) Content. Circ Res 129:650\u2013665. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318473","journal-title":"Circ Res"},{"key":"4520_CR132","doi-asserted-by":"publisher","first-page":"109","DOI":"10.17925\/EE.2020.16.2.109","volume":"16","author":"D Dutta","year":"2020","unstructured":"Dutta D, Sharma M, Sharma R (2020) Short-term hydroxychloroquine in COVID-19 infection in people with or without metabolic syndrome - clearing safety issues and good clinical practice. Eur Endocrinol 16:109\u2013112. https:\/\/doi.org\/10.17925\/EE.2020.16.2.109","journal-title":"Eur Endocrinol"},{"key":"4520_CR133","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijcard.2021.04.062","volume":"337","author":"L Ulander","year":"2021","unstructured":"Ulander L, Tolppanen H, Hartman O, Rissanen TT, Paakkanen R, Kuusisto J, Anttonen O, Nieminen T, Yrjola J, Ryysy R, Drews T, Utriainen S, Karjalainen P, Anttila I, Nurmi K, Silventoinen K, Koskinen M, Kovanen PT, Lehtonen J, Eklund KK, Sinisalo J (2021) Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: the randomized, double-blind, placebo-controlled OXI pilot trial. Int J Cardiol 337:21\u201327. https:\/\/doi.org\/10.1016\/j.ijcard.2021.04.062","journal-title":"Int J Cardiol"},{"key":"4520_CR134","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1517\/14728222.2015.1066337","volume":"19","author":"E Mandosi","year":"2015","unstructured":"Mandosi E, Giannetta E, Filardi T, Lococo M, Bertolini C, Fallarino M, Gianfrilli D, Venneri MA, Lenti L, Lenzi A, Morano S (2015) Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. Expert Opin Ther Targets 19:1617\u20131622. https:\/\/doi.org\/10.1517\/14728222.2015.1066337","journal-title":"Expert Opin Ther Targets"},{"key":"4520_CR135","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1210\/jc.2018-02525","volume":"104","author":"MA Venneri","year":"2019","unstructured":"Venneri MA, Barbagallo F, Fiore D, De Gaetano R, Giannetta E, Sbardella E, Pozza C, Campolo F, Naro F, Lenzi A, Isidori AM (2019) PDE5 inhibition stimulates Tie2-expressing monocytes and angiopoietin-1 restoring angiogenic homeostasis in diabetes. J Clin Endocrinol Metab 104:2623\u20132636. https:\/\/doi.org\/10.1210\/jc.2018-02525","journal-title":"J Clin Endocrinol Metab"},{"key":"4520_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.10.009","author":"R Pofi","year":"2020","unstructured":"Pofi R, Giannetta E, Galea N, Francone M, Campolo F, Barbagallo F, Gianfrilli D, Venneri MA, Filardi T, Cristini C, Antonini G, Badagliacca R, Frati G, Lenzi A, Carbone I, Isidori AM (2020) Diabetic cardiomiopathy progression is triggered by miR122-5p and involves extracellular matrix: a 5-year prospective study. JACC Cardiovasc Imaging. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.009","journal-title":"JACC Cardiovasc Imaging"},{"key":"4520_CR137","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00125-010-1819-4","volume":"53","author":"PA Jansson","year":"2010","unstructured":"Jansson PA, Murdolo G, Sjogren L, Nystrom B, Sjostrand M, Strindberg L, Lonnroth P (2010) Tadalafil increases muscle capillary recruitment and forearm glucose uptake in women with type 2 diabetes. Diabetologia 53:2205\u20132208. https:\/\/doi.org\/10.1007\/s00125-010-1819-4","journal-title":"Diabetologia"},{"key":"4520_CR138","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1681\/ASN.2015050473","volume":"27","author":"W Scheele","year":"2016","unstructured":"Scheele W, Diamond S, Gale J, Clerin V, Tamimi N, Le V, Walley R, Grover-Paez F, Perros-Huguet C, Rolph T, El Nahas M (2016) Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. J Am Soc Nephrol 27:3459\u20133468. https:\/\/doi.org\/10.1681\/ASN.2015050473","journal-title":"J Am Soc Nephrol"},{"key":"4520_CR139","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1530\/EJE-15-1100","volume":"174","author":"D Santi","year":"2016","unstructured":"Santi D, Granata AR, Guidi A, Pignatti E, Trenti T, Roli L, Bozic R, Zaza S, Pacchioni C, Romano S, Nofer JR, Rochira V, Carani C, Simoni M (2016) Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. Eur J Endocrinol 174:513\u2013522. https:\/\/doi.org\/10.1530\/EJE-15-1100","journal-title":"Eur J Endocrinol"},{"key":"4520_CR140","first-page":"E897","volume":"260","author":"JK Powrie","year":"1991","unstructured":"Powrie JK, Smith GD, Shojaee-Moradie F, Sonksen PH, Jones RH (1991) Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. Am J Physiol 260:E897\u2013E904","journal-title":"Am J Physiol"},{"key":"4520_CR141","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ehjcvp\/pvw035","volume":"3","author":"O Hartman","year":"2017","unstructured":"Hartman O, Kovanen PT, Lehtonen J, Eklund KK, Sinisalo J (2017) Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Eur Heart J Cardiovasc Pharmacother 3:92\u201397. https:\/\/doi.org\/10.1093\/ehjcvp\/pvw035","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4520_CR142","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40618-020-01330-5","volume":"44","author":"HN Chakravarti","year":"2021","unstructured":"Chakravarti HN, Nag A (2021) Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. J Endocrinol Invest 44:481\u2013492. https:\/\/doi.org\/10.1007\/s40618-020-01330-5","journal-title":"J Endocrinol Invest"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04520-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04520-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04520-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T22:35:53Z","timestamp":1676673353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04520-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4520"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04520-2","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no known competing financial interests or personal relationships that could have influenced the publication of this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. The present review article does not involve intervention on humans and\/or animals directly and it only analyzes and summarizes the information gathered from the published articles.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable. The present review article does not involve intervention on humans and\/or animals directly and it only analyzes and summarizes the information gathered from the published articles.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. The present review article does not involve intervention on humans and\/or animals directly and it only analyzes and summarizes the information gathered from the published articles.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}